Company intelligence / Profile preview

Jilin Shiyu Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Jilin Shiyu Pharmaceutical focuses on herbal medicines and has at least one approved drug, Suo Quan Wan, for pollakisuria. The drug received approval in China on July 24, 2020. No additional clinical results or pipeline programs are publicly disclosed beyond this single approved product as of early 2025.

Therapeutic areas: Nephrology
Modalities: Herbal medicine
Industry: Biotech

Beyond the preview

Go deeper on Jilin Shiyu Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jilin Shiyu Pharmaceutical.

Explore the full profile